Companies: 10,795·Total market cap: $144.5T
Amgen Inc.

Amgen Inc.

AMGNNASDAQHealthcare● Active
$349.58
+$3.98(+1.15%)
Market Cap$188.7B
P/E Ratio—
52W High$391.29
52W Low$267.83
Overview

Amgen Inc. (AMGN) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

AMGN · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$9.13B▼ -23.8% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$9.13B
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
-23.8%
vs prior fiscal year
Latest Quarter
$12.04B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$9.13BCash on Hand
Total Debt$54.60BTotal Debt
Net Cash / Net Debt−$45.48BNet Debt Position
Cash vs Debt Ratio
Cash 14%Debt 86%

Amgen Inc. carries a net debt position of $45.48B. Total debt ($54.60B) exceeds cash on hand ($9.13B). Amgen Inc. cash vs debt ratio: 14% cash / 86% debt.

Net Cash = Cash & ST Investments − Total Debt$9.13B − $54.60B = −$45.48B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
AMGN annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$9.13B-23.8%
Dec 31, 2024$11.97B+9.4%
Dec 31, 2023$10.94B+17.6%
Dec 31, 2022$9.30B+15.8%
Dec 31, 2021$8.04B-24.5%
AMGN cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
Amgen Inc.
Amgen Inc.YOU
AMGN
$9.13B4.8%
#4
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Amgen Inc. (AMGN) cash on hand as of December 31, 2025 is $9.13B, comprising $9.13B in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Amgen Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Amgen Inc. cash reserves or cash position.

Amgen Inc. annual cash on hand history shows decreased -23.8% in 2025: decreased -23.8% in 2025. Amgen Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Amgen Inc. carries total debt of $54.60B against cash of $9.13B, resulting in a net debt position of -$45.48B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

AMGN cash on hand · 5 questions

As of December 31, 2025, Amgen Inc. (AMGN) has $9.13B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $9.13B in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $12.04B. Data sourced from the annual 10-K filing via FMP.

AMGN cash on handAMGN cash reservesAMGN cash 2025how much cash does AMGN have

▸ Source: FMP /balance-sheet-statement · US GAAP · Amgen Inc. · Amgen Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025